Valerie Osborne · Advanced Skincare
Melasma
Best practice in pre-treatment, treatment and long-term management
A summary of published international consensus guidance, compiled for practitioners.
Free. No sign-up. Every source listed.
What this is
A protocol for best practice. It pulls a large body of peer-reviewed research and published international consensus guidance together into one place, so that you have it as a working reference rather than having to trawl the journals yourself.
It is not medical advice and it is not a prescribing guide. Every source is listed in full at the end, so you can read the original material and form your own view.
Section One
The Foundations
Relevant to every practitioner, medical or not.
1.1 What melasma actually is
Melasma is not a surface pigment problem. Treating it as one is the single most common reason protocols fail.
- It is chronic and relapsing. It cannot be cured. It is managed. Every consensus document says the same thing: ongoing maintenance therapy is required even after clinical remission.
- It is inflammatory and vascular, not just pigmentary. Lesional skin shows increased vascularity as well as increased pigment, confirmed by confocal microscopy. A systematic review in Dermatologic Surgery examined the vascular component specifically. Anything that dilates vessels or drives inflammation drives melasma.
- It is a photoaging condition of the dermis. Solar elastosis, basement membrane damage, fibroblast senescence and pigmentary incontinence all sit underneath the visible patch. Melanocyte numbers are not increased. The melanocytes present are larger, with more prominent dendrites, and are simply working harder.
- It is genetically loaded. In a global survey of 324 women, 48 per cent had a family history, and among those, 97 per cent had a first-degree relative affected.
- It carries a real psychological burden. Validated quality of life instruments exist specifically for this condition. It is not vanity, and it should not be treated as such in consultation.
The one line to use in consultation
Melasma is a long-term condition, like eczema or rosacea. We are going to get it quiet and then we are going to keep it quiet. Anyone who promises to clear it permanently is either misinformed or selling you something.
1.2 Who gets it: prevalence by Fitzpatrick type
The pattern is consistent across every major epidemiological study. Melasma clusters in the intermediate phototypes and is genuinely uncommon at both extremes. The American expert panel writing in the Journal of the American Academy of Dermatology puts global prevalence at approximately 1 per cent of the world population, predominantly affecting women, and more prevalent in skin of colour.
1.3 Hormones: the trigger practitioners underestimate
Hormones are not a background factor. For a large proportion of clients they are the actual driver, and no topical regimen will hold if the hormonal input is still running unchecked.
- Pregnancy. The classic trigger. Up to 50 per cent of women may be affected during pregnancy. Recurrence and aggravation in subsequent pregnancies is common. Rising oestrogen, progesterone and melanocyte-stimulating hormone in the third trimester are the presumed mechanism.
- Combined oral contraceptives. A case-control study of 207 melasma patients against 207 controls found combined oral contraceptives increased risk, with an odds ratio of 1.23.
- HRT and oestrogen or progesterone therapy. Patients with a history of oestrogen or progesterone therapy were twice as likely to develop melasma. Directly relevant to the perimenopausal and menopausal client.
- Thyroid disease and thyroid autoimmunity. Consistently associated. In one classic study, 70 per cent of women who developed melasma during pregnancy or on the pill had thyroid abnormalities, compared with 39.4 per cent of those with idiopathic melasma and 12.5 per cent of controls.
- Mechanism. Oestrogen and progesterone modulate melanogenesis through both genomic and non-genomic signalling, acting on the key enzymes and transcription factors of pigment synthesis, with crosstalk between the cascades that compounds the effect.
Practical consultation questions
Are you pregnant, planning a pregnancy, or breastfeeding? What contraception are you using, and has it changed recently? Are you on HRT, and did the pigmentation appear or worsen after starting it? Have you ever been told you have a thyroid problem, or had thyroid bloods taken? Did this start after a pregnancy? Does anyone in your family have it?
1.4 Heat, light and lifestyle: what to actually restrict
This is where the advice has moved furthest in the last decade, and where most practitioners are still giving outdated guidance. Sunscreen alone is not the answer. Heat is an independent trigger.
How to deliver this without losing the client
Do not hand someone a list of everything they must give up. Frame it as a clearance phase and a maintenance phase. Strict for twelve to sixteen weeks while the pigment comes down, then sensible and sustainable for life. People will accept a temporary restriction they would refuse as a permanent one.
Section Two
The Medical Standard of Care
What the published international consensus describes as standard practice. Included so that non-prescribing practitioners understand the wider clinical context and know when and why to refer.
Before you read this section
Several agents described below are prescription-only medicines. They are set out here as a factual summary of what the published clinical literature reports, not as a recommendation, and not as guidance on how to obtain or use them. Prescribing decisions belong to registered prescribers who have assessed the individual patient. If this section is relevant to a client of yours, the action it should prompt is a referral.
2.1 Cross-referencing the American and international literature
The guidance below is not one committee opinion. Two large bodies of work, one American and one international, arrive at essentially the same conclusions. Notably, several of the leading American pigmentation specialists sit on both.
The American expert view
- Best practices in the treatment of melasma with a focus on patients with skin of color. Published in the Journal of the American Academy of Dermatology in 2023 by Desai, Alexis, Elbuluk, Grimes, Weiss, Hamzavi and Taylor. The reference document from the American skin-of-colour specialists. It sets out a flexible treatment algorithm that explicitly separates a treatment period from a maintenance period, and reports strong histologic evidence supporting retinoids for epidermal melasma and microneedling for dermal melasma.
- Melasma Treatment: An Evidence-Based Review. McKesey, Tovar-Garza and Pandya, University of Texas Southwestern, American Journal of Clinical Dermatology, 2020. A systematic review of 113 studies covering 6,897 participants. Its conclusions are blunter than most marketing in this sector: hydroquinone monotherapy and triple combination cream are the most effective and best studied treatments; chemical peels and laser and light-based therapies are equal or inferior to topicals while carrying a higher risk of adverse effects; and oral tranexamic acid may be a safe systemic adjunct, though longer-term data is still needed.
- Amit Pandya developed the measurement tool. The Melasma Area and Severity Index and its modified version were validated by Pandya and colleagues. If you are using mMASI to track a client, you are using an American-validated instrument.
- Pearl Grimes has published extensively on newer agents, and Seemal Desai led a separate expert consensus on optimising melasma management with topical tranexamic acid.
Where they converge with the international consensus
The 2025 international Delphi consensus, published in the Journal of the European Academy of Dermatology and Venereology, included Seemal Desai, Susan Taylor, Nada Elbuluk and Henry Lim among its panel. It reached high consensus on essentially the same positions: photoprotection as essential, supervised hydroquinone-based triple combination as the gold standard, azelaic acid, kojic acid and oral tranexamic acid as alternatives, procedures as adjuncts rather than monotherapy, and lasers reserved for refractory cases.
Note
The American systematic review concluded that laser and light-based therapies are equal or inferior to topical treatment for melasma, and carry a higher risk of adverse effects. That is not a cautious European opinion. That is the conclusion of a review of 113 controlled studies out of UT Southwestern. If a device is being sold to a melasma client as the answer, the evidence is not on that side of the table.
2.2 The prescription arsenal
A factual summary of what the literature reports. Prescribing decisions rest with a registered prescriber.
2.3 The protocol: pre-treat, treat, post-treat
Worked for a Fitzpatrick III with moderate melasma. Adjust conservatively upward in caution for Types IV and V.
Phase one: prime, eight weeks minimum
Priming is not optional and it is not a formality. Consensus guidance is explicit that for patients at high risk of post-inflammatory hyperpigmentation, it is highly recommended to prime the skin with lightening agents before any procedural therapy.
- Wood lamp examination at baseline to determine whether pigment is epidermal, dermal or mixed. Dermal and mixed melasma responds far less well, and the client needs to be told that at the start, not at week twelve.
- Baseline photography under standardised lighting, plus a modified MASI score. Without a number you are relying on the client memory, which is unreliable in both directions.
- Topical suppression nightly. Tinted broad-spectrum SPF 50 with iron oxides every morning, reapplied.
- Systemic adjunct considered where appropriate, prescribed and screened by the prescriber.
- Full trigger review completed and agreed in writing. Heat, hormones, waxing, product irritants.
- Reassess at week 8 with repeat mMASI. Consensus practice is periodic reassessment every 8 to 12 weeks with adjustment if targets are not met.
The decision point at week eight
Greater than 30 per cent mMASI improvement: continue as established, and a device may now be considered. Less than 30 per cent improvement: do not escalate to a device. Intensify medical therapy and re-review. A device applied to uncontrolled melasma is the fastest route to an outcome worse than the starting point.
Phase two: in clinic
If, and only if, the melasma is suppressed and the client has demonstrated compliance.
- Wash out: stop tretinoin 7 days before, hydroquinone 5 to 7 days before, on the prescriber instruction. Continue SPF throughout.
- Conservative parameters. Low energy, low density or coverage, single pass, no stacking, no bulk heating.
- Active cooling throughout. Contact cooling, chilled air or a chiller through the pass. Heat is a trigger in its own right, so the goal is to deliver the effect with the minimum possible thermal load.
- Combining tranexamic acid with laser or light therapy reached high consensus as an acceptable approach, which supports keeping a systemic course running across the device phase where one has been prescribed.
- Interval of 4 to 6 weeks between sessions. Do not proceed to a second pass if the first produced any rebound pigmentation.
- Two to three sessions is a sensible ceiling. Judge on response, not on a pre-sold package. Selling melasma in packages is a commercial trap that pushes practitioners into treating when they should be waiting.
Phase three: post-treatment
- Barrier repair only for the first 5 to 7 days. Bland, non-fragranced, occlusive if needed.
- Absolute heat avoidance for 7 to 10 days. No sauna, no steam, no hot yoga, no hot showers on the face.
- Resume actives on the prescriber schedule, and only once erythema has fully settled. Residual redness at day 10 means resuming later, not on schedule.
- Tinted SPF 50 from day one, without exception.
- Review at 4 weeks with photography before any decision on a further session.
2.4 The hydroquinone holiday, explained
To be completely clear about the term
A hydroquinone holiday means a planned break from hydroquinone. It is the deliberate off phase in a cycled protocol, and it exists to reduce the risk of exogenous ochronosis, contact sensitisation and rebound pigmentation from continuous long-term use.
Hydroquinone is a clearance agent, not a maintenance agent. Run continuously it accumulates risk without accumulating benefit. The American expert algorithm makes the same structural point by separating a treatment period from a maintenance period.
Note
A melasma client is not a course of six. They are a long-term management relationship, reviewed quarterly, for years. Price and structure the offer accordingly. The clinic that sells a package of laser and sends them away is the clinic they leave. The clinic that manages them properly keeps them for a decade and gets every friend they have.
Section Three
The Non-Prescriber Protocol
For beauty therapists, advanced skincare therapists and non-medical skin professionals working in Ireland. What is available to you, what is not, and how to get an excellent result inside those limits.
3.1 The regulatory reality in Ireland
- Hydroquinone is off the table. Prohibited in cosmetic products across the EU under Regulation (EC) No 1223/2009, Annex II, entry 1339. There is no rinse-off or leave-on exception. Products found on the EU market are seized or recalled through the Safety Gate system. It is available in Ireland only through a prescriber.
- Tretinoin is prescription only. Non-prescribers work with cosmetic retinoids: retinol, retinaldehyde, retinyl esters, and hydroxypinacolone retinoate.
- Oral tranexamic acid is prescription only. Topical tranexamic acid is available cosmetically and is a genuinely useful tool.
- Know the EU concentration caps. Under amendment (EU) 2024/996, in force from 1 February 2025 for new products and 1 November 2025 for existing stock: alpha-arbutin is capped at 2 per cent in face creams and 0.5 per cent in body lotions, arbutin at 7 per cent in face creams, and kojic acid at 1 per cent in face and hand products. Niacinamide is permitted at 2 to 5 per cent in leave-on products.
- Be careful how you talk about prescription agents publicly. In Ireland, the Medicinal Products (Control of Advertising) Regulations 2007 prohibit the advertising of prescription-only medicines to the general public, and that prohibition applies to everyone, not only to pharmaceutical companies. Discussing prescription options with an individual client in a private consultation, in order to refer them, is a different matter from promoting those options publicly.
This is not a weaker protocol. It is a different one.
The prescription route gets there faster. The cosmetic route, run properly and given enough time, gets to a similar place and carries less risk of ochronosis, rebound and sensitisation. What it demands is patience and compliance, from you and from your client. Your job is to sell that patience convincingly.
3.2 The four pillars
Pillar one: tinted mineral SPF with iron oxides
This is not an add-on sale. This is the treatment. Everything else is secondary.
- SPF 50, broad spectrum, containing iron oxides. Iron oxides are what block visible light, and visible light drives melasma independently of UV.
- Tinted beats untinted. An untinted mineral sunscreen is significantly less effective here than a tinted one, and a conventional chemical sunscreen offers effectively nothing against visible light.
- Year-round and life-long, not seasonal. Irish clients treat sunscreen as a summer product and a holiday product. That is the exact belief to dismantle at consultation.
- Reapplication is where compliance dies. Give them a format they will actually use at eleven and at two. A compact, a cushion, a powder. The best sunscreen is the one that gets reapplied.
- Money wasted. Every euro spent on serums while wearing the wrong sunscreen is wasted.
Pillar two: a tyrosinase inhibitor
Tyrosinase is the rate-limiting enzyme in melanin synthesis. Inhibiting it is the mechanism hydroquinone uses, and there are cosmetic agents that act on the same enzyme. This is the pillar most non-prescriber protocols leave out, and leaving it out is why those protocols fail.
Pillar three: a cosmetic retinoid
- Retinol, retinaldehyde or hydroxypinacolone retinoate. Retinaldehyde is a useful middle ground: closer to tretinoin in potency than retinol, and better tolerated than most clients expect.
- Introduce low and slow. Twice weekly, building over eight to twelve weeks. A high-strength retinoid introduced too fast causes irritation, and irritation worsens melasma. This is the most common own goal in a therapist-led protocol.
- If the skin is red, stinging or peeling, you have gone too fast and you are actively making the pigment worse. Pull back immediately.
- Not during pregnancy or breastfeeding. Use azelaic acid and niacinamide instead.
Pillar four: antioxidants
- Vitamin C, vitamin E, ferulic acid, polyphenols. Melasma involves UV-induced oxidative stress and dermal inflammation, so this is mechanistically justified rather than a nice extra.
- Morning application, under the tinted SPF. Antioxidants and sunscreen are a partnership, not alternatives.
- Oral antioxidants are endorsed in consensus guidance as systemic adjuncts. Polypodium leucotomos is the most commonly used in practice.
3.3 How long to pre-treat
Longer than the prescription route. This is the single most important number in this section, and it is the one clients and therapists both want to shorten.
Twelve weeks minimum. Say it at consultation, not at week six.
A prescriber can prime in eight weeks because the triple combination is doing heavy lifting from night one. Cosmetic actives need twelve, and often sixteen. Set that expectation in the first appointment, in writing, and the client stays with you. Set it at week six when they ask why nothing has happened and you lose them.
3.4 In clinic: what is safe and what is not
3.5 When to refer
Referring well is a professional strength, and clients respect it. It also protects you.
- No meaningful improvement after 16 weeks of a well-executed and genuinely compliant cosmetic protocol.
- Dermal or mixed melasma identified on Wood lamp examination.
- A suspected hormonal driver that needs medical review, particularly HRT, contraception or a possible thyroid issue.
- Any pigmented lesion that is asymmetric, changing rapidly, bleeding or painful. That is not melasma until a doctor says it is, and it is not yours to treat.
- A client who wants, and would benefit from, options that only a prescriber can provide.
- Diagnostic uncertainty of any kind. Not everything brown on a face is melasma.
Build the referral relationship before you need it
Have a named GP, dermatologist or prescribing colleague you can send to and who will send back. A client referred out and managed medically almost always returns for the maintenance work, and returns trusting you more than before. That trust is worth more than the treatment you did not sell.
3.6 Glossary of terms
Section Four
Sources and Further Reading
Every clinical claim above traces back to the sources below. Read them yourself and form your own view.
4.1 American expert sources
Desai SR, Alexis AF, Elbuluk N, Grimes PE, Weiss J, Hamzavi IH, Taylor SC. Journal of the American Academy of Dermatology, 2023.
The American reference document, written by seven of the leading skin-of-colour and pigmentation specialists in the United States. Sets out a treatment algorithm that separates a treatment period from a maintenance period.
McKesey J, Tovar-Garza A, Pandya AG. American Journal of Clinical Dermatology, 2020.
The most rigorous systematic review available: 113 studies, 6,897 participants. The single most quotable source in this guide.
Dermatologic Surgery.
The evidence behind treating melasma as a vascular as well as a pigmentary condition. Useful background for explaining why heat, flushing and inflammation matter so much.
American Journal of Clinical Dermatology, 2024.
The most current American overview. Covers newer agents and the expert consensus on topical tranexamic acid.
Medscape, continuously updated.
Free, clinically detailed and heavily referenced. A practical starting point without journal access.
4.2 International consensus and reviews
Journal of the European Academy of Dermatology and Venereology, 2026.
The current international benchmark. Twenty-one statements reached high consensus. If you read one thing, this is it.
International Journal of Dermatology, 2025. Open access.
Practical and algorithmic. Contains the mMASI decision framework that underpins the escalation logic above.
Clinical, Cosmetic and Investigational Dermatology, 2023. Open access.
The pathophysiology paper. Explains why melasma is a dermal and vascular condition rather than a surface pigment deposit.
Handel AC, Miot LDB, Miot HA. Anais Brasileiros de Dermatologia, 2014. Open access.
The source of most of the Fitzpatrick prevalence data quoted above.
StatPearls, National Center for Biotechnology Information.
Free, comprehensive, continuously updated and written at clinical level.
Frontiers in Pharmacology, 2024. Open access.
Every topical, systemic and procedural option, with an honest account of where each falls short.
Open access literature review.
Everything on tranexamic acid in one place, covering oral, topical and intradermal routes and the safety profile.
Open access, 2023.
Balanced account of efficacy against side effects, and the international regulatory position including the EU cosmetic ban.
4.3 Patient-friendly resources
DermNet, New Zealand.
The best all-round resource on this list. The one to send a client home with.
British Association of Dermatologists, Patient Hub.
Written and readability-tested specifically for patients by a national dermatology body. Calm, non-commercial and authoritative.
British Association of Dermatologists, June 2024.
The printable version, for handing something physical to a client at the end of a consultation.
Cleveland Clinic.
Very accessible. Covers the hormonal triggers in plain language and lists the everyday aggravators.
Section Five
Important Notice and Terms of Use
This notice forms part of this material and applies to all of it. Please read it before using anything set out above.
1. This is educational material, not medical advice
This has been prepared for educational and informational purposes only. It is a summary of publicly available, peer-reviewed clinical literature and published international consensus guidance on the management of melasma. It does not constitute medical advice, diagnosis, or treatment, and it must not be relied upon as a substitute for consultation with a doctor, dermatologist, pharmacist, or other appropriately qualified and registered healthcare professional.
2. The author is not a medical practitioner
Valerie Osborne is an aesthetic practitioner, clinic owner and educator with more than twenty years of experience in the aesthetics industry. She is not a doctor, dermatologist, nurse, pharmacist or prescriber. She does not diagnose medical conditions and she is not qualified or authorised to prescribe, recommend or supply prescription medicines. Where prescription-only agents are described, they are described only to explain what the published clinical literature reports about them, so that non-prescribing practitioners understand the wider context in which they work and can recognise when to refer a client onward. Nothing here is a recommendation to use, obtain or supply any prescription medicine.
3. Prescription medicines and referral
A number of the agents discussed in Section Two are classified as prescription-only medicines in Ireland and in most other jurisdictions. They may lawfully be prescribed only by a registered prescriber, following an individual clinical assessment of the patient, and they carry contraindications and potential adverse effects that are not fully described here. They must never be obtained from unregulated sources, imported privately, or supplied by anyone not legally authorised to do so. If you or your client wish to explore these options, the correct and only route is a referral to a GP, dermatologist or other registered prescriber.
4. No practitioner or client relationship is created
Reading, downloading or applying this information does not create a professional, clinical or advisory relationship of any kind between the reader and Valerie Osborne or Elysium Skincare Clinic. No responsibility or liability is accepted for any action taken, or not taken, on the basis of the information contained here.
5. Practitioners remain responsible for their own practice
If you are a practitioner, you remain solely responsible for working within your own scope of practice, qualifications, training, insurance and the law of the country in which you practise. You are responsible for satisfying yourself as to the regulatory status of any product or device you use, for obtaining informed consent, and for carrying appropriate professional indemnity cover. Regulations governing cosmetic ingredients, medical devices and medicines differ between jurisdictions and change over time. Check the current position for your own country before acting.
6. Currency and accuracy
The clinical guidance summarised here reflects published literature and consensus statements available at the time of writing. Medicine changes. Guidance is superseded. Every effort has been made to represent the sources accurately, but no warranty is given as to completeness or continued accuracy, and readers are encouraged to consult the primary sources in Section Four directly.
7. No commercial endorsement
No brand, product, device or manufacturer is endorsed here, and no payment or commercial consideration has been received in connection with the preparation of this material. Ingredients and agents are referred to generically.
8. Seek medical attention where appropriate
If you have a skin concern, particularly a pigmented area that is changing, asymmetric, bleeding, painful or growing, seek assessment from a doctor without delay. Not all facial pigmentation is melasma, and some conditions that resemble it require urgent medical attention.
Valerie Osborne · Advanced Skincare
Melasma
Best practice in pre-treatment, treatment and long-term management
A summary of published international consensus guidance, compiled for practitioners.
Free. No sign-up. Every source listed.
What this is
A protocol for best practice. It pulls a large body of peer-reviewed research and published international consensus guidance together into one place, so that you have it as a working reference rather than having to trawl the journals yourself.
It is not medical advice and it is not a prescribing guide. Every source is listed in full at the end, so you can read the original material and form your own view.
Section One
The Foundations
Relevant to every practitioner, medical or not.
1.1 What melasma actually is
Melasma is not a surface pigment problem. Treating it as one is the single most common reason protocols fail.
- It is chronic and relapsing. It cannot be cured. It is managed. Every consensus document says the same thing: ongoing maintenance therapy is required even after clinical remission.
- It is inflammatory and vascular, not just pigmentary. Lesional skin shows increased vascularity as well as increased pigment, confirmed by confocal microscopy. A systematic review in Dermatologic Surgery examined the vascular component specifically. Anything that dilates vessels or drives inflammation drives melasma.
- It is a photoaging condition of the dermis. Solar elastosis, basement membrane damage, fibroblast senescence and pigmentary incontinence all sit underneath the visible patch. Melanocyte numbers are not increased. The melanocytes present are larger, with more prominent dendrites, and are simply working harder.
- It is genetically loaded. In a global survey of 324 women, 48 per cent had a family history, and among those, 97 per cent had a first-degree relative affected.
- It carries a real psychological burden. Validated quality of life instruments exist specifically for this condition. It is not vanity, and it should not be treated as such in consultation.
The one line to use in consultation
Melasma is a long-term condition, like eczema or rosacea. We are going to get it quiet and then we are going to keep it quiet. Anyone who promises to clear it permanently is either misinformed or selling you something.
1.2 Who gets it: prevalence by Fitzpatrick type
The pattern is consistent across every major epidemiological study. Melasma clusters in the intermediate phototypes and is genuinely uncommon at both extremes. The American expert panel writing in the Journal of the American Academy of Dermatology puts global prevalence at approximately 1 per cent of the world population, predominantly affecting women, and more prevalent in skin of colour.
Read this before quoting a number
There is no single reliable global prevalence figure for melasma. Rates vary enormously by geography, ancestry and whether a study was clinic-based or community-based. Reported figures range from under 9 per cent in a Latino population in Texas to 39.5 per cent in a study of 855 Iranian women. Quote the pattern, not a headline percentage.
1.3 Hormones: the trigger practitioners underestimate
Hormones are not a background factor. For a large proportion of clients they are the actual driver, and no topical regimen will hold if the hormonal input is still running unchecked.
- Pregnancy. The classic trigger. Up to 50 per cent of women may be affected during pregnancy. Recurrence and aggravation in subsequent pregnancies is common. Rising oestrogen, progesterone and melanocyte-stimulating hormone in the third trimester are the presumed mechanism.
- Combined oral contraceptives. A case-control study of 207 melasma patients against 207 controls found combined oral contraceptives increased risk, with an odds ratio of 1.23.
- HRT and oestrogen or progesterone therapy. Patients with a history of oestrogen or progesterone therapy were twice as likely to develop melasma. Directly relevant to the perimenopausal and menopausal client.
- Thyroid disease and thyroid autoimmunity. Consistently associated. In one classic study, 70 per cent of women who developed melasma during pregnancy or on the pill had thyroid abnormalities, compared with 39.4 per cent of those with idiopathic melasma and 12.5 per cent of controls.
- Mechanism. Oestrogen and progesterone modulate melanogenesis through both genomic and non-genomic signalling, acting on the key enzymes and transcription factors of pigment synthesis, with crosstalk between the cascades that compounds the effect.
Practical consultation questions
Are you pregnant, planning a pregnancy, or breastfeeding? What contraception are you using, and has it changed recently? Are you on HRT, and did the pigmentation appear or worsen after starting it? Have you ever been told you have a thyroid problem, or had thyroid bloods taken? Did this start after a pregnancy? Does anyone in your family have it?
1.4 Heat, light and lifestyle: what to actually restrict
This is where the advice has moved furthest in the last decade, and where most practitioners are still giving outdated guidance. Sunscreen alone is not the answer. Heat is an independent trigger.
How to deliver this without losing the client
Do not hand someone a list of everything they must give up. Frame it as a clearance phase and a maintenance phase. Strict for twelve to sixteen weeks while the pigment comes down, then sensible and sustainable for life. People will accept a temporary restriction they would refuse as a permanent one.
Section Two
The Medical Standard of Care
What the published international consensus describes as standard practice. Included so that non-prescribing practitioners understand the wider clinical context and know when and why to refer.
Before you read this section
Several agents described below are prescription-only medicines. They are set out here as a factual summary of what the published clinical literature reports, not as a recommendation, and not as guidance on how to obtain or use them. Prescribing decisions belong to registered prescribers who have assessed the individual patient. If this section is relevant to a client of yours, the action it should prompt is a referral.
2.1 Cross-referencing the American and international literature
The guidance below is not one committee opinion. Two large bodies of work, one American and one international, arrive at essentially the same conclusions. Notably, several of the leading American pigmentation specialists sit on both.
The American expert view
- Best practices in the treatment of melasma with a focus on patients with skin of color. Published in the Journal of the American Academy of Dermatology in 2023 by Desai, Alexis, Elbuluk, Grimes, Weiss, Hamzavi and Taylor. The reference document from the American skin-of-colour specialists. It sets out a flexible treatment algorithm that explicitly separates a treatment period from a maintenance period, and reports strong histologic evidence supporting retinoids for epidermal melasma and microneedling for dermal melasma.
- Melasma Treatment: An Evidence-Based Review. McKesey, Tovar-Garza and Pandya, University of Texas Southwestern, American Journal of Clinical Dermatology, 2020. A systematic review of 113 studies covering 6,897 participants. Its conclusions are blunter than most marketing in this sector: hydroquinone monotherapy and triple combination cream are the most effective and best studied treatments; chemical peels and laser and light-based therapies are equal or inferior to topicals while carrying a higher risk of adverse effects; and oral tranexamic acid may be a safe systemic adjunct, though longer-term data is still needed.
- Amit Pandya developed the measurement tool. The Melasma Area and Severity Index and its modified version were validated by Pandya and colleagues. If you are using mMASI to track a client, you are using an American-validated instrument.
- Pearl Grimes has published extensively on newer agents, and Seemal Desai led a separate expert consensus on optimising melasma management with topical tranexamic acid.
Where they converge with the international consensus
The 2025 international Delphi consensus, published in the Journal of the European Academy of Dermatology and Venereology, included Seemal Desai, Susan Taylor, Nada Elbuluk and Henry Lim among its panel. It reached high consensus on essentially the same positions: photoprotection as essential, supervised hydroquinone-based triple combination as the gold standard, azelaic acid, kojic acid and oral tranexamic acid as alternatives, procedures as adjuncts rather than monotherapy, and lasers reserved for refractory cases.
The line worth remembering
The American systematic review concluded that laser and light-based therapies are equal or inferior to topical treatment for melasma, and carry a higher risk of adverse effects. That is not a cautious European opinion. That is the conclusion of a review of 113 controlled studies out of UT Southwestern. If a device is being sold to a melasma client as the answer, the evidence is not on that side of the table.
2.2 The prescription arsenal
A factual summary of what the literature reports. Prescribing decisions rest with a registered prescriber.
2.3 The protocol: pre-treat, treat, post-treat
Worked for a Fitzpatrick III with moderate melasma. Adjust conservatively upward in caution for Types IV and V.
Phase one: prime, eight weeks minimum
Priming is not optional and it is not a formality. Consensus guidance is explicit that for patients at high risk of post-inflammatory hyperpigmentation, it is highly recommended to prime the skin with lightening agents before any procedural therapy.
- Wood lamp examination at baseline to determine whether pigment is epidermal, dermal or mixed. Dermal and mixed melasma responds far less well, and the client needs to be told that at the start, not at week twelve.
- Baseline photography under standardised lighting, plus a modified MASI score. Without a number you are relying on the client memory, which is unreliable in both directions.
- Topical suppression nightly. Tinted broad-spectrum SPF 50 with iron oxides every morning, reapplied.
- Systemic adjunct considered where appropriate, prescribed and screened by the prescriber.
- Full trigger review completed and agreed in writing. Heat, hormones, waxing, product irritants.
- Reassess at week 8 with repeat mMASI. Consensus practice is periodic reassessment every 8 to 12 weeks with adjustment if targets are not met.
The decision point at week eight
Greater than 30 per cent mMASI improvement: continue as established, and a device may now be considered. Less than 30 per cent improvement: do not escalate to a device. Intensify medical therapy and re-review. A device applied to uncontrolled melasma is the fastest route to an outcome worse than the starting point.
Phase two: in clinic
If, and only if, the melasma is suppressed and the client has demonstrated compliance.
- Wash out: stop tretinoin 7 days before, hydroquinone 5 to 7 days before, on the prescriber instruction. Continue SPF throughout.
- Conservative parameters. Low energy, low density or coverage, single pass, no stacking, no bulk heating.
- Active cooling throughout. Contact cooling, chilled air or a chiller through the pass. Heat is a trigger in its own right, so the goal is to deliver the effect with the minimum possible thermal load.
- Combining tranexamic acid with laser or light therapy reached high consensus as an acceptable approach, which supports keeping a systemic course running across the device phase where one has been prescribed.
- Interval of 4 to 6 weeks between sessions. Do not proceed to a second pass if the first produced any rebound pigmentation.
- Two to three sessions is a sensible ceiling. Judge on response, not on a pre-sold package. Selling melasma in packages is a commercial trap that pushes practitioners into treating when they should be waiting.
Phase three: post-treatment
- Barrier repair only for the first 5 to 7 days. Bland, non-fragranced, occlusive if needed.
- Absolute heat avoidance for 7 to 10 days. No sauna, no steam, no hot yoga, no hot showers on the face.
- Resume actives on the prescriber schedule, and only once erythema has fully settled. Residual redness at day 10 means resuming later, not on schedule.
- Tinted SPF 50 from day one, without exception.
- Review at 4 weeks with photography before any decision on a further session.
2.4 The hydroquinone holiday, explained
To be completely clear about the term
A hydroquinone holiday means a planned break from hydroquinone. It has nothing to do with a sun holiday. It is the deliberate off phase in a cycled protocol, and it exists to reduce the risk of exogenous ochronosis, contact sensitisation and rebound pigmentation from continuous long-term use.
Hydroquinone is a clearance agent, not a maintenance agent. Run continuously it accumulates risk without accumulating benefit. The American expert algorithm makes the same structural point by separating a treatment period from a maintenance period.
Know your worth on this one
A melasma client is not a course of six. They are a long-term management relationship, reviewed quarterly, for years. Price and structure the offer accordingly. The clinic that sells a package of laser and sends them away is the clinic they leave. The clinic that manages them properly keeps them for a decade and gets every friend they have.
Section Three
The Non-Prescriber Protocol
For beauty therapists, advanced skincare therapists and non-medical skin professionals working in Ireland. What is available to you, what is not, and how to get an excellent result inside those limits.
3.1 The regulatory reality in Ireland
- Hydroquinone is off the table. Prohibited in cosmetic products across the EU under Regulation (EC) No 1223/2009, Annex II, entry 1339. There is no rinse-off or leave-on exception. Products found on the EU market are seized or recalled through the Safety Gate system. It is available in Ireland only through a prescriber.
- Tretinoin is prescription only. Non-prescribers work with cosmetic retinoids: retinol, retinaldehyde, retinyl esters, and hydroxypinacolone retinoate.
- Oral tranexamic acid is prescription only. Topical tranexamic acid is available cosmetically and is a genuinely useful tool.
- Know the EU concentration caps. Under amendment (EU) 2024/996, in force from 1 February 2025 for new products and 1 November 2025 for existing stock: alpha-arbutin is capped at 2 per cent in face creams and 0.5 per cent in body lotions, arbutin at 7 per cent in face creams, and kojic acid at 1 per cent in face and hand products. Niacinamide is permitted at 2 to 5 per cent in leave-on products.
- Be careful how you talk about prescription agents publicly. In Ireland, the Medicinal Products (Control of Advertising) Regulations 2007 prohibit the advertising of prescription-only medicines to the general public, and that prohibition applies to everyone, not only to pharmaceutical companies. Discussing prescription options with an individual client in a private consultation, in order to refer them, is a different matter from promoting those options publicly.
This is not a weaker protocol. It is a different one.
The prescription route gets there faster. The cosmetic route, run properly and given enough time, gets to a similar place and carries less risk of ochronosis, rebound and sensitisation. What it demands is patience and compliance, from you and from your client. Your job is to sell that patience convincingly.
3.2 The four pillars
Pillar one: tinted mineral SPF with iron oxides
This is not an add-on sale. This is the treatment. Everything else is secondary.
- SPF 50, broad spectrum, containing iron oxides. Iron oxides are what block visible light, and visible light drives melasma independently of UV.
- Tinted beats untinted. An untinted mineral sunscreen is significantly less effective here than a tinted one, and a conventional chemical sunscreen offers effectively nothing against visible light.
- Year-round and life-long, not seasonal. Irish clients treat sunscreen as a summer product and a holiday product. That is the exact belief to dismantle at consultation.
- Reapplication is where compliance dies. Give them a format they will actually use at eleven and at two. A compact, a cushion, a powder. The best sunscreen is the one that gets reapplied.
- Money wasted. Every euro spent on serums while wearing the wrong sunscreen is wasted, and you should say so plainly. It is not rude. It is the most useful thing you will say to that client.
Pillar two: a tyrosinase inhibitor
Tyrosinase is the rate-limiting enzyme in melanin synthesis. Inhibiting it is the mechanism hydroquinone uses, and there are cosmetic agents that act on the same enzyme. This is the pillar most non-prescriber protocols leave out, and leaving it out is why those protocols fail.
Pillar three: a cosmetic retinoid
- Retinol, retinaldehyde or hydroxypinacolone retinoate. Retinaldehyde is a useful middle ground: closer to tretinoin in potency than retinol, and better tolerated than most clients expect.
- Introduce low and slow. Twice weekly, building over eight to twelve weeks. A high-strength retinoid introduced too fast causes irritation, and irritation worsens melasma. This is the most common own goal in a therapist-led protocol.
- If the skin is red, stinging or peeling, you have gone too fast and you are actively making the pigment worse. Pull back immediately.
- Not during pregnancy or breastfeeding. Use azelaic acid and niacinamide instead.
Pillar four: antioxidants
- Vitamin C, vitamin E, ferulic acid, polyphenols. Melasma involves UV-induced oxidative stress and dermal inflammation, so this is mechanistically justified rather than a nice extra.
- Morning application, under the tinted SPF. Antioxidants and sunscreen are a partnership, not alternatives.
- Oral antioxidants are endorsed in consensus guidance as systemic adjuncts. Polypodium leucotomos is the most commonly used in practice.
3.3 How long to pre-treat
Longer than the prescription route. This is the single most important number in this section, and it is the one clients and therapists both want to shorten.
Twelve weeks minimum. Say it at consultation, not at week six.
A prescriber can prime in eight weeks because the triple combination is doing heavy lifting from night one. Cosmetic actives need twelve, and often sixteen. Set that expectation in the first appointment, in writing, and the client stays with you. Set it at week six when they ask why nothing has happened and you lose them.
3.4 In clinic: what is safe and what is not
3.5 When to refer
Referring well is a professional strength, and clients respect it. It also protects you.
- No meaningful improvement after 16 weeks of a well-executed and genuinely compliant cosmetic protocol.
- Dermal or mixed melasma identified on Wood lamp examination.
- A suspected hormonal driver that needs medical review, particularly HRT, contraception or a possible thyroid issue.
- Any pigmented lesion that is asymmetric, changing rapidly, bleeding or painful. That is not melasma until a doctor says it is, and it is not yours to treat.
- A client who wants, and would benefit from, options that only a prescriber can provide.
- Diagnostic uncertainty of any kind. Not everything brown on a face is melasma.
Build the referral relationship before you need it
Have a named GP, dermatologist or prescribing colleague you can send to and who will send back. A client referred out and managed medically almost always returns for the maintenance work, and returns trusting you more than before. That trust is worth more than the treatment you did not sell.
3.6 Glossary of terms
Section Four
Sources and Further Reading
Every clinical claim above traces back to the sources below. Read them yourself and form your own view.
4.1 American expert sources
Desai SR, Alexis AF, Elbuluk N, Grimes PE, Weiss J, Hamzavi IH, Taylor SC. Journal of the American Academy of Dermatology, 2023.
The American reference document, written by seven of the leading skin-of-colour and pigmentation specialists in the United States. Sets out a treatment algorithm that separates a treatment period from a maintenance period.
McKesey J, Tovar-Garza A, Pandya AG. American Journal of Clinical Dermatology, 2020.
The most rigorous systematic review available: 113 studies, 6,897 participants. The single most quotable source in this guide.
Dermatologic Surgery.
The evidence behind treating melasma as a vascular as well as a pigmentary condition. Useful background for explaining why heat, flushing and inflammation matter so much.
American Journal of Clinical Dermatology, 2024.
The most current American overview. Covers newer agents and the expert consensus on topical tranexamic acid.
Medscape, continuously updated.
Free, clinically detailed and heavily referenced. A practical starting point without journal access.
4.2 International consensus and reviews
Journal of the European Academy of Dermatology and Venereology, 2026.
The current international benchmark. Twenty-one statements reached high consensus. If you read one thing, this is it.
International Journal of Dermatology, 2025. Open access.
Practical and algorithmic. Contains the mMASI decision framework that underpins the escalation logic above.
Clinical, Cosmetic and Investigational Dermatology, 2023. Open access.
The pathophysiology paper. Explains why melasma is a dermal and vascular condition rather than a surface pigment deposit.
Handel AC, Miot LDB, Miot HA. Anais Brasileiros de Dermatologia, 2014. Open access.
The source of most of the Fitzpatrick prevalence data quoted above.
StatPearls, National Center for Biotechnology Information.
Free, comprehensive, continuously updated and written at clinical level.
Frontiers in Pharmacology, 2024. Open access.
Every topical, systemic and procedural option, with an honest account of where each falls short.
Open access literature review.
Everything on tranexamic acid in one place, covering oral, topical and intradermal routes and the safety profile.
Open access, 2023.
Balanced account of efficacy against side effects, and the international regulatory position including the EU cosmetic ban.
4.3 Patient-friendly resources
DermNet, New Zealand.
The best all-round resource on this list. The one to send a client home with.
British Association of Dermatologists, Patient Hub.
Written and readability-tested specifically for patients by a national dermatology body. Calm, non-commercial and authoritative.
British Association of Dermatologists, June 2024.
The printable version, for handing something physical to a client at the end of a consultation.
Cleveland Clinic.
Very accessible. Covers the hormonal triggers in plain language and lists the everyday aggravators.
Section Five
Important Notice and Terms of Use
This notice forms part of this material and applies to all of it. Please read it before using anything set out above.
1. This is educational material, not medical advice
This has been prepared for educational and informational purposes only. It is a summary of publicly available, peer-reviewed clinical literature and published international consensus guidance on the management of melasma. It does not constitute medical advice, diagnosis, or treatment, and it must not be relied upon as a substitute for consultation with a doctor, dermatologist, pharmacist, or other appropriately qualified and registered healthcare professional.
2. The author is not a medical practitioner
Valerie Osborne is an aesthetic practitioner, clinic owner and educator with more than twenty years of experience in the aesthetics industry. She is not a doctor, dermatologist, nurse, pharmacist or prescriber. She does not diagnose medical conditions and she is not qualified or authorised to prescribe, recommend or supply prescription medicines. Where prescription-only agents are described, they are described only to explain what the published clinical literature reports about them, so that non-prescribing practitioners understand the wider context in which they work and can recognise when to refer a client onward. Nothing here is a recommendation to use, obtain or supply any prescription medicine.
3. Prescription medicines and referral
A number of the agents discussed in Section Two are classified as prescription-only medicines in Ireland and in most other jurisdictions. They may lawfully be prescribed only by a registered prescriber, following an individual clinical assessment of the patient, and they carry contraindications and potential adverse effects that are not fully described here. They must never be obtained from unregulated sources, imported privately, or supplied by anyone not legally authorised to do so. If you or your client wish to explore these options, the correct and only route is a referral to a GP, dermatologist or other registered prescriber.
4. No practitioner or client relationship is created
Reading, downloading or applying this information does not create a professional, clinical or advisory relationship of any kind between the reader and Valerie Osborne or Elysium Skincare Clinic. No responsibility or liability is accepted for any action taken, or not taken, on the basis of the information contained here.
5. Practitioners remain responsible for their own practice
If you are a practitioner, you remain solely responsible for working within your own scope of practice, qualifications, training, insurance and the law of the country in which you practise. You are responsible for satisfying yourself as to the regulatory status of any product or device you use, for obtaining informed consent, and for carrying appropriate professional indemnity cover. Regulations governing cosmetic ingredients, medical devices and medicines differ between jurisdictions and change over time. Check the current position for your own country before acting.
6. Currency and accuracy
The clinical guidance summarised here reflects published literature and consensus statements available at the time of writing. Medicine changes. Guidance is superseded. Every effort has been made to represent the sources accurately, but no warranty is given as to completeness or continued accuracy, and readers are encouraged to consult the primary sources in Section Four directly.
7. No commercial endorsement
No brand, product, device or manufacturer is endorsed here, and no payment or commercial consideration has been received in connection with the preparation of this material. Ingredients and agents are referred to generically.
8. Seek medical attention where appropriate
If you have a skin concern, particularly a pigmented area that is changing, asymmetric, bleeding, painful or growing, seek assessment from a doctor without delay. Not all facial pigmentation is melasma, and some conditions that resemble it require urgent medical attention.
Valerie Osborne · Advanced Skincare
Melasma
Best practice in pre-treatment, treatment and long-term management
A summary of published international consensus guidance, compiled for practitioners.
Free. No sign-up. Every source listed.
What this is
A protocol for best practice. It pulls a large body of peer-reviewed research and published international consensus guidance together into one place, so that you have it as a working reference rather than having to trawl the journals yourself.
It is not medical advice and it is not a prescribing guide. Every source is listed in full at the end, so you can read the original material and form your own view.
Section One
The Foundations
Relevant to every practitioner, medical or not.
1.1 What melasma actually is
Melasma is not a surface pigment problem. Treating it as one is the single most common reason protocols fail.
- It is chronic and relapsing. It cannot be cured. It is managed. Every consensus document says the same thing: ongoing maintenance therapy is required even after clinical remission.
- It is inflammatory and vascular, not just pigmentary. Lesional skin shows increased vascularity as well as increased pigment, confirmed by confocal microscopy. A systematic review in Dermatologic Surgery examined the vascular component specifically. Anything that dilates vessels or drives inflammation drives melasma.
- It is a photoaging condition of the dermis. Solar elastosis, basement membrane damage, fibroblast senescence and pigmentary incontinence all sit underneath the visible patch. Melanocyte numbers are not increased. The melanocytes present are larger, with more prominent dendrites, and are simply working harder.
- It is genetically loaded. In a global survey of 324 women, 48 per cent had a family history, and among those, 97 per cent had a first-degree relative affected.
- It carries a real psychological burden. Validated quality of life instruments exist specifically for this condition. It is not vanity, and it should not be treated as such in consultation.
The one line to use in consultation
Melasma is a long-term condition, like eczema or rosacea. We are going to get it quiet and then we are going to keep it quiet. Anyone who promises to clear it permanently is either misinformed or selling you something.
1.2 Who gets it: prevalence by Fitzpatrick type
The pattern is consistent across every major epidemiological study. Melasma clusters in the intermediate phototypes and is genuinely uncommon at both extremes. The American expert panel writing in the Journal of the American Academy of Dermatology puts global prevalence at approximately 1 per cent of the world population, predominantly affecting women, and more prevalent in skin of colour.
Read this before quoting a number
There is no single reliable global prevalence figure for melasma. Rates vary enormously by geography, ancestry and whether a study was clinic-based or community-based. Reported figures range from under 9 per cent in a Latino population in Texas to 39.5 per cent in a study of 855 Iranian women. Quote the pattern, not a headline percentage.
1.3 Hormones: the trigger practitioners underestimate
Hormones are not a background factor. For a large proportion of clients they are the actual driver, and no topical regimen will hold if the hormonal input is still running unchecked.
- Pregnancy. The classic trigger. Up to 50 per cent of women may be affected during pregnancy. Recurrence and aggravation in subsequent pregnancies is common. Rising oestrogen, progesterone and melanocyte-stimulating hormone in the third trimester are the presumed mechanism.
- Combined oral contraceptives. A case-control study of 207 melasma patients against 207 controls found combined oral contraceptives increased risk, with an odds ratio of 1.23.
- HRT and oestrogen or progesterone therapy. Patients with a history of oestrogen or progesterone therapy were twice as likely to develop melasma. Directly relevant to the perimenopausal and menopausal client.
- Thyroid disease and thyroid autoimmunity. Consistently associated. In one classic study, 70 per cent of women who developed melasma during pregnancy or on the pill had thyroid abnormalities, compared with 39.4 per cent of those with idiopathic melasma and 12.5 per cent of controls.
- Mechanism. Oestrogen and progesterone modulate melanogenesis through both genomic and non-genomic signalling, acting on the key enzymes and transcription factors of pigment synthesis, with crosstalk between the cascades that compounds the effect.
Practical consultation questions
Are you pregnant, planning a pregnancy, or breastfeeding? What contraception are you using, and has it changed recently? Are you on HRT, and did the pigmentation appear or worsen after starting it? Have you ever been told you have a thyroid problem, or had thyroid bloods taken? Did this start after a pregnancy? Does anyone in your family have it?
1.4 Heat, light and lifestyle: what to actually restrict
This is where the advice has moved furthest in the last decade, and where most practitioners are still giving outdated guidance. Sunscreen alone is not the answer. Heat is an independent trigger.
How to deliver this without losing the client
Do not hand someone a list of everything they must give up. Frame it as a clearance phase and a maintenance phase. Strict for twelve to sixteen weeks while the pigment comes down, then sensible and sustainable for life. People will accept a temporary restriction they would refuse as a permanent one.
Section Two
The Medical Standard of Care
What the published international consensus describes as standard practice. Included so that non-prescribing practitioners understand the wider clinical context and know when and why to refer.
Before you read this section
Several agents described below are prescription-only medicines. They are set out here as a factual summary of what the published clinical literature reports, not as a recommendation, and not as guidance on how to obtain or use them. Prescribing decisions belong to registered prescribers who have assessed the individual patient. If this section is relevant to a client of yours, the action it should prompt is a referral.
2.1 Cross-referencing the American and international literature
The guidance below is not one committee opinion. Two large bodies of work, one American and one international, arrive at essentially the same conclusions. Notably, several of the leading American pigmentation specialists sit on both.
The American expert view
- Best practices in the treatment of melasma with a focus on patients with skin of color. Published in the Journal of the American Academy of Dermatology in 2023 by Desai, Alexis, Elbuluk, Grimes, Weiss, Hamzavi and Taylor. The reference document from the American skin-of-colour specialists. It sets out a flexible treatment algorithm that explicitly separates a treatment period from a maintenance period, and reports strong histologic evidence supporting retinoids for epidermal melasma and microneedling for dermal melasma.
- Melasma Treatment: An Evidence-Based Review. McKesey, Tovar-Garza and Pandya, University of Texas Southwestern, American Journal of Clinical Dermatology, 2020. A systematic review of 113 studies covering 6,897 participants. Its conclusions are blunter than most marketing in this sector: hydroquinone monotherapy and triple combination cream are the most effective and best studied treatments; chemical peels and laser and light-based therapies are equal or inferior to topicals while carrying a higher risk of adverse effects; and oral tranexamic acid may be a safe systemic adjunct, though longer-term data is still needed.
- Amit Pandya developed the measurement tool. The Melasma Area and Severity Index and its modified version were validated by Pandya and colleagues. If you are using mMASI to track a client, you are using an American-validated instrument.
- Pearl Grimes has published extensively on newer agents, and Seemal Desai led a separate expert consensus on optimising melasma management with topical tranexamic acid.
Where they converge with the international consensus
The 2025 international Delphi consensus, published in the Journal of the European Academy of Dermatology and Venereology, included Seemal Desai, Susan Taylor, Nada Elbuluk and Henry Lim among its panel. It reached high consensus on essentially the same positions: photoprotection as essential, supervised hydroquinone-based triple combination as the gold standard, azelaic acid, kojic acid and oral tranexamic acid as alternatives, procedures as adjuncts rather than monotherapy, and lasers reserved for refractory cases.
The line worth remembering
The American systematic review concluded that laser and light-based therapies are equal or inferior to topical treatment for melasma, and carry a higher risk of adverse effects. That is not a cautious European opinion. That is the conclusion of a review of 113 controlled studies out of UT Southwestern. If a device is being sold to a melasma client as the answer, the evidence is not on that side of the table.
2.2 The prescription arsenal
A factual summary of what the literature reports. Prescribing decisions rest with a registered prescriber.
2.3 The protocol: pre-treat, treat, post-treat
Worked for a Fitzpatrick III with moderate melasma. Adjust conservatively upward in caution for Types IV and V.
Phase one: prime, eight weeks minimum
Priming is not optional and it is not a formality. Consensus guidance is explicit that for patients at high risk of post-inflammatory hyperpigmentation, it is highly recommended to prime the skin with lightening agents before any procedural therapy.
- Wood lamp examination at baseline to determine whether pigment is epidermal, dermal or mixed. Dermal and mixed melasma responds far less well, and the client needs to be told that at the start, not at week twelve.
- Baseline photography under standardised lighting, plus a modified MASI score. Without a number you are relying on the client memory, which is unreliable in both directions.
- Topical suppression nightly. Tinted broad-spectrum SPF 50 with iron oxides every morning, reapplied.
- Systemic adjunct considered where appropriate, prescribed and screened by the prescriber.
- Full trigger review completed and agreed in writing. Heat, hormones, waxing, product irritants.
- Reassess at week 8 with repeat mMASI. Consensus practice is periodic reassessment every 8 to 12 weeks with adjustment if targets are not met.
The decision point at week eight
Greater than 30 per cent mMASI improvement: continue as established, and a device may now be considered. Less than 30 per cent improvement: do not escalate to a device. Intensify medical therapy and re-review. A device applied to uncontrolled melasma is the fastest route to an outcome worse than the starting point.
Phase two: in clinic
If, and only if, the melasma is suppressed and the client has demonstrated compliance.
- Wash out: stop tretinoin 7 days before, hydroquinone 5 to 7 days before, on the prescriber instruction. Continue SPF throughout.
- Conservative parameters. Low energy, low density or coverage, single pass, no stacking, no bulk heating.
- Active cooling throughout. Contact cooling, chilled air or a chiller through the pass. Heat is a trigger in its own right, so the goal is to deliver the effect with the minimum possible thermal load.
- Combining tranexamic acid with laser or light therapy reached high consensus as an acceptable approach, which supports keeping a systemic course running across the device phase where one has been prescribed.
- Interval of 4 to 6 weeks between sessions. Do not proceed to a second pass if the first produced any rebound pigmentation.
- Two to three sessions is a sensible ceiling. Judge on response, not on a pre-sold package. Selling melasma in packages is a commercial trap that pushes practitioners into treating when they should be waiting.
Phase three: post-treatment
- Barrier repair only for the first 5 to 7 days. Bland, non-fragranced, occlusive if needed.
- Absolute heat avoidance for 7 to 10 days. No sauna, no steam, no hot yoga, no hot showers on the face.
- Resume actives on the prescriber schedule, and only once erythema has fully settled. Residual redness at day 10 means resuming later, not on schedule.
- Tinted SPF 50 from day one, without exception.
- Review at 4 weeks with photography before any decision on a further session.
2.4 The hydroquinone holiday, explained
To be completely clear about the term
A hydroquinone holiday means a planned break from hydroquinone. It has nothing to do with a sun holiday. It is the deliberate off phase in a cycled protocol, and it exists to reduce the risk of exogenous ochronosis, contact sensitisation and rebound pigmentation from continuous long-term use.
Hydroquinone is a clearance agent, not a maintenance agent. Run continuously it accumulates risk without accumulating benefit. The American expert algorithm makes the same structural point by separating a treatment period from a maintenance period.
Know your worth on this one
A melasma client is not a course of six. They are a long-term management relationship, reviewed quarterly, for years. Price and structure the offer accordingly. The clinic that sells a package of laser and sends them away is the clinic they leave. The clinic that manages them properly keeps them for a decade and gets every friend they have.
Section Three
The Non-Prescriber Protocol
For beauty therapists, advanced skincare therapists and non-medical skin professionals working in Ireland. What is available to you, what is not, and how to get an excellent result inside those limits.
3.1 The regulatory reality in Ireland
- Hydroquinone is off the table. Prohibited in cosmetic products across the EU under Regulation (EC) No 1223/2009, Annex II, entry 1339. There is no rinse-off or leave-on exception. Products found on the EU market are seized or recalled through the Safety Gate system. It is available in Ireland only through a prescriber.
- Tretinoin is prescription only. Non-prescribers work with cosmetic retinoids: retinol, retinaldehyde, retinyl esters, and hydroxypinacolone retinoate.
- Oral tranexamic acid is prescription only. Topical tranexamic acid is available cosmetically and is a genuinely useful tool.
- Know the EU concentration caps. Under amendment (EU) 2024/996, in force from 1 February 2025 for new products and 1 November 2025 for existing stock: alpha-arbutin is capped at 2 per cent in face creams and 0.5 per cent in body lotions, arbutin at 7 per cent in face creams, and kojic acid at 1 per cent in face and hand products. Niacinamide is permitted at 2 to 5 per cent in leave-on products.
- Be careful how you talk about prescription agents publicly. In Ireland, the Medicinal Products (Control of Advertising) Regulations 2007 prohibit the advertising of prescription-only medicines to the general public, and that prohibition applies to everyone, not only to pharmaceutical companies. Discussing prescription options with an individual client in a private consultation, in order to refer them, is a different matter from promoting those options publicly.
This is not a weaker protocol. It is a different one.
The prescription route gets there faster. The cosmetic route, run properly and given enough time, gets to a similar place and carries less risk of ochronosis, rebound and sensitisation. What it demands is patience and compliance, from you and from your client. Your job is to sell that patience convincingly.
3.2 The four pillars
Pillar one: tinted mineral SPF with iron oxides
This is not an add-on sale. This is the treatment. Everything else is secondary.
- SPF 50, broad spectrum, containing iron oxides. Iron oxides are what block visible light, and visible light drives melasma independently of UV.
- Tinted beats untinted. An untinted mineral sunscreen is significantly less effective here than a tinted one, and a conventional chemical sunscreen offers effectively nothing against visible light.
- Year-round and life-long, not seasonal. Irish clients treat sunscreen as a summer product and a holiday product. That is the exact belief to dismantle at consultation.
- Reapplication is where compliance dies. Give them a format they will actually use at eleven and at two. A compact, a cushion, a powder. The best sunscreen is the one that gets reapplied.
- Money wasted. Every euro spent on serums while wearing the wrong sunscreen is wasted, and you should say so plainly. It is not rude. It is the most useful thing you will say to that client.
Pillar two: a tyrosinase inhibitor
Tyrosinase is the rate-limiting enzyme in melanin synthesis. Inhibiting it is the mechanism hydroquinone uses, and there are cosmetic agents that act on the same enzyme. This is the pillar most non-prescriber protocols leave out, and leaving it out is why those protocols fail.
Pillar three: a cosmetic retinoid
- Retinol, retinaldehyde or hydroxypinacolone retinoate. Retinaldehyde is a useful middle ground: closer to tretinoin in potency than retinol, and better tolerated than most clients expect.
- Introduce low and slow. Twice weekly, building over eight to twelve weeks. A high-strength retinoid introduced too fast causes irritation, and irritation worsens melasma. This is the most common own goal in a therapist-led protocol.
- If the skin is red, stinging or peeling, you have gone too fast and you are actively making the pigment worse. Pull back immediately.
- Not during pregnancy or breastfeeding. Use azelaic acid and niacinamide instead.
Pillar four: antioxidants
- Vitamin C, vitamin E, ferulic acid, polyphenols. Melasma involves UV-induced oxidative stress and dermal inflammation, so this is mechanistically justified rather than a nice extra.
- Morning application, under the tinted SPF. Antioxidants and sunscreen are a partnership, not alternatives.
- Oral antioxidants are endorsed in consensus guidance as systemic adjuncts. Polypodium leucotomos is the most commonly used in practice.
3.3 How long to pre-treat
Longer than the prescription route. This is the single most important number in this section, and it is the one clients and therapists both want to shorten.
Twelve weeks minimum. Say it at consultation, not at week six.
A prescriber can prime in eight weeks because the triple combination is doing heavy lifting from night one. Cosmetic actives need twelve, and often sixteen. Set that expectation in the first appointment, in writing, and the client stays with you. Set it at week six when they ask why nothing has happened and you lose them.
3.4 In clinic: what is safe and what is not
3.5 When to refer
Referring well is a professional strength, and clients respect it. It also protects you.
- No meaningful improvement after 16 weeks of a well-executed and genuinely compliant cosmetic protocol.
- Dermal or mixed melasma identified on Wood lamp examination.
- A suspected hormonal driver that needs medical review, particularly HRT, contraception or a possible thyroid issue.
- Any pigmented lesion that is asymmetric, changing rapidly, bleeding or painful. That is not melasma until a doctor says it is, and it is not yours to treat.
- A client who wants, and would benefit from, options that only a prescriber can provide.
- Diagnostic uncertainty of any kind. Not everything brown on a face is melasma.
Build the referral relationship before you need it
Have a named GP, dermatologist or prescribing colleague you can send to and who will send back. A client referred out and managed medically almost always returns for the maintenance work, and returns trusting you more than before. That trust is worth more than the treatment you did not sell.
3.6 Glossary of terms
Section Four
Sources and Further Reading
Every clinical claim above traces back to the sources below. Read them yourself and form your own view.
4.1 American expert sources
Desai SR, Alexis AF, Elbuluk N, Grimes PE, Weiss J, Hamzavi IH, Taylor SC. Journal of the American Academy of Dermatology, 2023.
The American reference document, written by seven of the leading skin-of-colour and pigmentation specialists in the United States. Sets out a treatment algorithm that separates a treatment period from a maintenance period.
McKesey J, Tovar-Garza A, Pandya AG. American Journal of Clinical Dermatology, 2020.
The most rigorous systematic review available: 113 studies, 6,897 participants. The single most quotable source in this guide.
Dermatologic Surgery.
The evidence behind treating melasma as a vascular as well as a pigmentary condition. Useful background for explaining why heat, flushing and inflammation matter so much.
American Journal of Clinical Dermatology, 2024.
The most current American overview. Covers newer agents and the expert consensus on topical tranexamic acid.
Medscape, continuously updated.
Free, clinically detailed and heavily referenced. A practical starting point without journal access.
4.2 International consensus and reviews
Journal of the European Academy of Dermatology and Venereology, 2026.
The current international benchmark. Twenty-one statements reached high consensus. If you read one thing, this is it.
International Journal of Dermatology, 2025. Open access.
Practical and algorithmic. Contains the mMASI decision framework that underpins the escalation logic above.
Clinical, Cosmetic and Investigational Dermatology, 2023. Open access.
The pathophysiology paper. Explains why melasma is a dermal and vascular condition rather than a surface pigment deposit.
Handel AC, Miot LDB, Miot HA. Anais Brasileiros de Dermatologia, 2014. Open access.
The source of most of the Fitzpatrick prevalence data quoted above.
StatPearls, National Center for Biotechnology Information.
Free, comprehensive, continuously updated and written at clinical level.
Frontiers in Pharmacology, 2024. Open access.
Every topical, systemic and procedural option, with an honest account of where each falls short.
Open access literature review.
Everything on tranexamic acid in one place, covering oral, topical and intradermal routes and the safety profile.
Open access, 2023.
Balanced account of efficacy against side effects, and the international regulatory position including the EU cosmetic ban.
4.3 Patient-friendly resources
DermNet, New Zealand.
The best all-round resource on this list. The one to send a client home with.
British Association of Dermatologists, Patient Hub.
Written and readability-tested specifically for patients by a national dermatology body. Calm, non-commercial and authoritative.
British Association of Dermatologists, June 2024.
The printable version, for handing something physical to a client at the end of a consultation.
Cleveland Clinic.
Very accessible. Covers the hormonal triggers in plain language and lists the everyday aggravators.
Section Five
Important Notice and Terms of Use
This notice forms part of this material and applies to all of it. Please read it before using anything set out above.
1. This is educational material, not medical advice
This has been prepared for educational and informational purposes only. It is a summary of publicly available, peer-reviewed clinical literature and published international consensus guidance on the management of melasma. It does not constitute medical advice, diagnosis, or treatment, and it must not be relied upon as a substitute for consultation with a doctor, dermatologist, pharmacist, or other appropriately qualified and registered healthcare professional.
2. The author is not a medical practitioner
Valerie Osborne is an aesthetic practitioner, clinic owner and educator with more than twenty years of experience in the aesthetics industry. She is not a doctor, dermatologist, nurse, pharmacist or prescriber. She does not diagnose medical conditions and she is not qualified or authorised to prescribe, recommend or supply prescription medicines. Where prescription-only agents are described, they are described only to explain what the published clinical literature reports about them, so that non-prescribing practitioners understand the wider context in which they work and can recognise when to refer a client onward. Nothing here is a recommendation to use, obtain or supply any prescription medicine.
3. Prescription medicines and referral
A number of the agents discussed in Section Two are classified as prescription-only medicines in Ireland and in most other jurisdictions. They may lawfully be prescribed only by a registered prescriber, following an individual clinical assessment of the patient, and they carry contraindications and potential adverse effects that are not fully described here. They must never be obtained from unregulated sources, imported privately, or supplied by anyone not legally authorised to do so. If you or your client wish to explore these options, the correct and only route is a referral to a GP, dermatologist or other registered prescriber.
4. No practitioner or client relationship is created
Reading, downloading or applying this information does not create a professional, clinical or advisory relationship of any kind between the reader and Valerie Osborne or Elysium Skincare Clinic. No responsibility or liability is accepted for any action taken, or not taken, on the basis of the information contained here.
5. Practitioners remain responsible for their own practice
If you are a practitioner, you remain solely responsible for working within your own scope of practice, qualifications, training, insurance and the law of the country in which you practise. You are responsible for satisfying yourself as to the regulatory status of any product or device you use, for obtaining informed consent, and for carrying appropriate professional indemnity cover. Regulations governing cosmetic ingredients, medical devices and medicines differ between jurisdictions and change over time. Check the current position for your own country before acting.
6. Currency and accuracy
The clinical guidance summarised here reflects published literature and consensus statements available at the time of writing. Medicine changes. Guidance is superseded. Every effort has been made to represent the sources accurately, but no warranty is given as to completeness or continued accuracy, and readers are encouraged to consult the primary sources in Section Four directly.
7. No commercial endorsement
No brand, product, device or manufacturer is endorsed here, and no payment or commercial consideration has been received in connection with the preparation of this material. Ingredients and agents are referred to generically.
8. Seek medical attention where appropriate
If you have a skin concern, particularly a pigmented area that is changing, asymmetric, bleeding, painful or growing, seek assessment from a doctor without delay. Not all facial pigmentation is melasma, and some conditions that resemble it require urgent medical attention.
Valerie Osborne · Advanced Skincare
Melasma
Best practice in pre-treatment, treatment and long-term management
A summary of published international consensus guidance, compiled for practitioners.
Free. No sign-up. Every source listed.
What this is
A protocol for best practice. It pulls a large body of peer-reviewed research and published international consensus guidance together into one place, so that you have it as a working reference rather than having to trawl the journals yourself.
It is not medical advice and it is not a prescribing guide. Every source is listed in full at the end, so you can read the original material and form your own view.
Section One
The Foundations
Relevant to every practitioner, medical or not.
1.1 What melasma actually is
Melasma is not a surface pigment problem. Treating it as one is the single most common reason protocols fail.
- It is chronic and relapsing. It cannot be cured. It is managed. Every consensus document says the same thing: ongoing maintenance therapy is required even after clinical remission.
- It is inflammatory and vascular, not just pigmentary. Lesional skin shows increased vascularity as well as increased pigment, confirmed by confocal microscopy. A systematic review in Dermatologic Surgery examined the vascular component specifically. Anything that dilates vessels or drives inflammation drives melasma.
- It is a photoaging condition of the dermis. Solar elastosis, basement membrane damage, fibroblast senescence and pigmentary incontinence all sit underneath the visible patch. Melanocyte numbers are not increased. The melanocytes present are larger, with more prominent dendrites, and are simply working harder.
- It is genetically loaded. In a global survey of 324 women, 48 per cent had a family history, and among those, 97 per cent had a first-degree relative affected.
- It carries a real psychological burden. Validated quality of life instruments exist specifically for this condition. It is not vanity, and it should not be treated as such in consultation.
The one line to use in consultation
Melasma is a long-term condition, like eczema or rosacea. We are going to get it quiet and then we are going to keep it quiet. Anyone who promises to clear it permanently is either misinformed or selling you something.
1.2 Who gets it: prevalence by Fitzpatrick type
The pattern is consistent across every major epidemiological study. Melasma clusters in the intermediate phototypes and is genuinely uncommon at both extremes. The American expert panel writing in the Journal of the American Academy of Dermatology puts global prevalence at approximately 1 per cent of the world population, predominantly affecting women, and more prevalent in skin of colour.
Read this before quoting a number
There is no single reliable global prevalence figure for melasma. Rates vary enormously by geography, ancestry and whether a study was clinic-based or community-based. Reported figures range from under 9 per cent in a Latino population in Texas to 39.5 per cent in a study of 855 Iranian women. Quote the pattern, not a headline percentage.
1.3 Hormones: the trigger practitioners underestimate
Hormones are not a background factor. For a large proportion of clients they are the actual driver, and no topical regimen will hold if the hormonal input is still running unchecked.
- Pregnancy. The classic trigger. Up to 50 per cent of women may be affected during pregnancy. Recurrence and aggravation in subsequent pregnancies is common. Rising oestrogen, progesterone and melanocyte-stimulating hormone in the third trimester are the presumed mechanism.
- Combined oral contraceptives. A case-control study of 207 melasma patients against 207 controls found combined oral contraceptives increased risk, with an odds ratio of 1.23.
- HRT and oestrogen or progesterone therapy. Patients with a history of oestrogen or progesterone therapy were twice as likely to develop melasma. Directly relevant to the perimenopausal and menopausal client.
- Thyroid disease and thyroid autoimmunity. Consistently associated. In one classic study, 70 per cent of women who developed melasma during pregnancy or on the pill had thyroid abnormalities, compared with 39.4 per cent of those with idiopathic melasma and 12.5 per cent of controls.
- Mechanism. Oestrogen and progesterone modulate melanogenesis through both genomic and non-genomic signalling, acting on the key enzymes and transcription factors of pigment synthesis, with crosstalk between the cascades that compounds the effect.
Practical consultation questions
Are you pregnant, planning a pregnancy, or breastfeeding? What contraception are you using, and has it changed recently? Are you on HRT, and did the pigmentation appear or worsen after starting it? Have you ever been told you have a thyroid problem, or had thyroid bloods taken? Did this start after a pregnancy? Does anyone in your family have it?
1.4 Heat, light and lifestyle: what to actually restrict
This is where the advice has moved furthest in the last decade, and where most practitioners are still giving outdated guidance. Sunscreen alone is not the answer. Heat is an independent trigger.
How to deliver this without losing the client
Do not hand someone a list of everything they must give up. Frame it as a clearance phase and a maintenance phase. Strict for twelve to sixteen weeks while the pigment comes down, then sensible and sustainable for life. People will accept a temporary restriction they would refuse as a permanent one.
Section Two
The Medical Standard of Care
What the published international consensus describes as standard practice. Included so that non-prescribing practitioners understand the wider clinical context and know when and why to refer.
Before you read this section
Several agents described below are prescription-only medicines. They are set out here as a factual summary of what the published clinical literature reports, not as a recommendation, and not as guidance on how to obtain or use them. Prescribing decisions belong to registered prescribers who have assessed the individual patient. If this section is relevant to a client of yours, the action it should prompt is a referral.
2.1 Cross-referencing the American and international literature
The guidance below is not one committee opinion. Two large bodies of work, one American and one international, arrive at essentially the same conclusions. Notably, several of the leading American pigmentation specialists sit on both.
The American expert view
- Best practices in the treatment of melasma with a focus on patients with skin of color. Published in the Journal of the American Academy of Dermatology in 2023 by Desai, Alexis, Elbuluk, Grimes, Weiss, Hamzavi and Taylor. The reference document from the American skin-of-colour specialists. It sets out a flexible treatment algorithm that explicitly separates a treatment period from a maintenance period, and reports strong histologic evidence supporting retinoids for epidermal melasma and microneedling for dermal melasma.
- Melasma Treatment: An Evidence-Based Review. McKesey, Tovar-Garza and Pandya, University of Texas Southwestern, American Journal of Clinical Dermatology, 2020. A systematic review of 113 studies covering 6,897 participants. Its conclusions are blunter than most marketing in this sector: hydroquinone monotherapy and triple combination cream are the most effective and best studied treatments; chemical peels and laser and light-based therapies are equal or inferior to topicals while carrying a higher risk of adverse effects; and oral tranexamic acid may be a safe systemic adjunct, though longer-term data is still needed.
- Amit Pandya developed the measurement tool. The Melasma Area and Severity Index and its modified version were validated by Pandya and colleagues. If you are using mMASI to track a client, you are using an American-validated instrument.
- Pearl Grimes has published extensively on newer agents, and Seemal Desai led a separate expert consensus on optimising melasma management with topical tranexamic acid.
Where they converge with the international consensus
The 2025 international Delphi consensus, published in the Journal of the European Academy of Dermatology and Venereology, included Seemal Desai, Susan Taylor, Nada Elbuluk and Henry Lim among its panel. It reached high consensus on essentially the same positions: photoprotection as essential, supervised hydroquinone-based triple combination as the gold standard, azelaic acid, kojic acid and oral tranexamic acid as alternatives, procedures as adjuncts rather than monotherapy, and lasers reserved for refractory cases.
The line worth remembering
The American systematic review concluded that laser and light-based therapies are equal or inferior to topical treatment for melasma, and carry a higher risk of adverse effects. That is not a cautious European opinion. That is the conclusion of a review of 113 controlled studies out of UT Southwestern. If a device is being sold to a melasma client as the answer, the evidence is not on that side of the table.
2.2 The prescription arsenal
A factual summary of what the literature reports. Prescribing decisions rest with a registered prescriber.
2.3 The protocol: pre-treat, treat, post-treat
Worked for a Fitzpatrick III with moderate melasma. Adjust conservatively upward in caution for Types IV and V.
Phase one: prime, eight weeks minimum
Priming is not optional and it is not a formality. Consensus guidance is explicit that for patients at high risk of post-inflammatory hyperpigmentation, it is highly recommended to prime the skin with lightening agents before any procedural therapy.
- Wood lamp examination at baseline to determine whether pigment is epidermal, dermal or mixed. Dermal and mixed melasma responds far less well, and the client needs to be told that at the start, not at week twelve.
- Baseline photography under standardised lighting, plus a modified MASI score. Without a number you are relying on the client memory, which is unreliable in both directions.
- Topical suppression nightly. Tinted broad-spectrum SPF 50 with iron oxides every morning, reapplied.
- Systemic adjunct considered where appropriate, prescribed and screened by the prescriber.
- Full trigger review completed and agreed in writing. Heat, hormones, waxing, product irritants.
- Reassess at week 8 with repeat mMASI. Consensus practice is periodic reassessment every 8 to 12 weeks with adjustment if targets are not met.
The decision point at week eight
Greater than 30 per cent mMASI improvement: continue as established, and a device may now be considered. Less than 30 per cent improvement: do not escalate to a device. Intensify medical therapy and re-review. A device applied to uncontrolled melasma is the fastest route to an outcome worse than the starting point.
Phase two: in clinic
If, and only if, the melasma is suppressed and the client has demonstrated compliance.
- Wash out: stop tretinoin 7 days before, hydroquinone 5 to 7 days before, on the prescriber instruction. Continue SPF throughout.
- Conservative parameters. Low energy, low density or coverage, single pass, no stacking, no bulk heating.
- Active cooling throughout. Contact cooling, chilled air or a chiller through the pass. Heat is a trigger in its own right, so the goal is to deliver the effect with the minimum possible thermal load.
- Combining tranexamic acid with laser or light therapy reached high consensus as an acceptable approach, which supports keeping a systemic course running across the device phase where one has been prescribed.
- Interval of 4 to 6 weeks between sessions. Do not proceed to a second pass if the first produced any rebound pigmentation.
- Two to three sessions is a sensible ceiling. Judge on response, not on a pre-sold package. Selling melasma in packages is a commercial trap that pushes practitioners into treating when they should be waiting.
Phase three: post-treatment
- Barrier repair only for the first 5 to 7 days. Bland, non-fragranced, occlusive if needed.
- Absolute heat avoidance for 7 to 10 days. No sauna, no steam, no hot yoga, no hot showers on the face.
- Resume actives on the prescriber schedule, and only once erythema has fully settled. Residual redness at day 10 means resuming later, not on schedule.
- Tinted SPF 50 from day one, without exception.
- Review at 4 weeks with photography before any decision on a further session.
2.4 The hydroquinone holiday, explained
To be completely clear about the term
A hydroquinone holiday means a planned break from hydroquinone. It has nothing to do with a sun holiday. It is the deliberate off phase in a cycled protocol, and it exists to reduce the risk of exogenous ochronosis, contact sensitisation and rebound pigmentation from continuous long-term use.
Hydroquinone is a clearance agent, not a maintenance agent. Run continuously it accumulates risk without accumulating benefit. The American expert algorithm makes the same structural point by separating a treatment period from a maintenance period.
Know your worth on this one
A melasma client is not a course of six. They are a long-term management relationship, reviewed quarterly, for years. Price and structure the offer accordingly. The clinic that sells a package of laser and sends them away is the clinic they leave. The clinic that manages them properly keeps them for a decade and gets every friend they have.
Section Three
The Non-Prescriber Protocol
For beauty therapists, advanced skincare therapists and non-medical skin professionals working in Ireland. What is available to you, what is not, and how to get an excellent result inside those limits.
3.1 The regulatory reality in Ireland
- Hydroquinone is off the table. Prohibited in cosmetic products across the EU under Regulation (EC) No 1223/2009, Annex II, entry 1339. There is no rinse-off or leave-on exception. Products found on the EU market are seized or recalled through the Safety Gate system. It is available in Ireland only through a prescriber.
- Tretinoin is prescription only. Non-prescribers work with cosmetic retinoids: retinol, retinaldehyde, retinyl esters, and hydroxypinacolone retinoate.
- Oral tranexamic acid is prescription only. Topical tranexamic acid is available cosmetically and is a genuinely useful tool.
- Know the EU concentration caps. Under amendment (EU) 2024/996, in force from 1 February 2025 for new products and 1 November 2025 for existing stock: alpha-arbutin is capped at 2 per cent in face creams and 0.5 per cent in body lotions, arbutin at 7 per cent in face creams, and kojic acid at 1 per cent in face and hand products. Niacinamide is permitted at 2 to 5 per cent in leave-on products.
- Be careful how you talk about prescription agents publicly. In Ireland, the Medicinal Products (Control of Advertising) Regulations 2007 prohibit the advertising of prescription-only medicines to the general public, and that prohibition applies to everyone, not only to pharmaceutical companies. Discussing prescription options with an individual client in a private consultation, in order to refer them, is a different matter from promoting those options publicly.
This is not a weaker protocol. It is a different one.
The prescription route gets there faster. The cosmetic route, run properly and given enough time, gets to a similar place and carries less risk of ochronosis, rebound and sensitisation. What it demands is patience and compliance, from you and from your client. Your job is to sell that patience convincingly.
3.2 The four pillars
Pillar one: tinted mineral SPF with iron oxides
This is not an add-on sale. This is the treatment. Everything else is secondary.
- SPF 50, broad spectrum, containing iron oxides. Iron oxides are what block visible light, and visible light drives melasma independently of UV.
- Tinted beats untinted. An untinted mineral sunscreen is significantly less effective here than a tinted one, and a conventional chemical sunscreen offers effectively nothing against visible light.
- Year-round and life-long, not seasonal. Irish clients treat sunscreen as a summer product and a holiday product. That is the exact belief to dismantle at consultation.
- Reapplication is where compliance dies. Give them a format they will actually use at eleven and at two. A compact, a cushion, a powder. The best sunscreen is the one that gets reapplied.
- Money wasted. Every euro spent on serums while wearing the wrong sunscreen is wasted, and you should say so plainly. It is not rude. It is the most useful thing you will say to that client.
Pillar two: a tyrosinase inhibitor
Tyrosinase is the rate-limiting enzyme in melanin synthesis. Inhibiting it is the mechanism hydroquinone uses, and there are cosmetic agents that act on the same enzyme. This is the pillar most non-prescriber protocols leave out, and leaving it out is why those protocols fail.
Pillar three: a cosmetic retinoid
- Retinol, retinaldehyde or hydroxypinacolone retinoate. Retinaldehyde is a useful middle ground: closer to tretinoin in potency than retinol, and better tolerated than most clients expect.
- Introduce low and slow. Twice weekly, building over eight to twelve weeks. A high-strength retinoid introduced too fast causes irritation, and irritation worsens melasma. This is the most common own goal in a therapist-led protocol.
- If the skin is red, stinging or peeling, you have gone too fast and you are actively making the pigment worse. Pull back immediately.
- Not during pregnancy or breastfeeding. Use azelaic acid and niacinamide instead.
Pillar four: antioxidants
- Vitamin C, vitamin E, ferulic acid, polyphenols. Melasma involves UV-induced oxidative stress and dermal inflammation, so this is mechanistically justified rather than a nice extra.
- Morning application, under the tinted SPF. Antioxidants and sunscreen are a partnership, not alternatives.
- Oral antioxidants are endorsed in consensus guidance as systemic adjuncts. Polypodium leucotomos is the most commonly used in practice.
3.3 How long to pre-treat
Longer than the prescription route. This is the single most important number in this section, and it is the one clients and therapists both want to shorten.
Twelve weeks minimum. Say it at consultation, not at week six.
A prescriber can prime in eight weeks because the triple combination is doing heavy lifting from night one. Cosmetic actives need twelve, and often sixteen. Set that expectation in the first appointment, in writing, and the client stays with you. Set it at week six when they ask why nothing has happened and you lose them.
3.4 In clinic: what is safe and what is not
3.5 When to refer
Referring well is a professional strength, and clients respect it. It also protects you.
- No meaningful improvement after 16 weeks of a well-executed and genuinely compliant cosmetic protocol.
- Dermal or mixed melasma identified on Wood lamp examination.
- A suspected hormonal driver that needs medical review, particularly HRT, contraception or a possible thyroid issue.
- Any pigmented lesion that is asymmetric, changing rapidly, bleeding or painful. That is not melasma until a doctor says it is, and it is not yours to treat.
- A client who wants, and would benefit from, options that only a prescriber can provide.
- Diagnostic uncertainty of any kind. Not everything brown on a face is melasma.
Build the referral relationship before you need it
Have a named GP, dermatologist or prescribing colleague you can send to and who will send back. A client referred out and managed medically almost always returns for the maintenance work, and returns trusting you more than before. That trust is worth more than the treatment you did not sell.
3.6 Glossary of terms
Section Four
Sources and Further Reading
Every clinical claim above traces back to the sources below. Read them yourself and form your own view.
4.1 American expert sources
Desai SR, Alexis AF, Elbuluk N, Grimes PE, Weiss J, Hamzavi IH, Taylor SC. Journal of the American Academy of Dermatology, 2023.
The American reference document, written by seven of the leading skin-of-colour and pigmentation specialists in the United States. Sets out a treatment algorithm that separates a treatment period from a maintenance period.
McKesey J, Tovar-Garza A, Pandya AG. American Journal of Clinical Dermatology, 2020.
The most rigorous systematic review available: 113 studies, 6,897 participants. The single most quotable source in this guide.
Dermatologic Surgery.
The evidence behind treating melasma as a vascular as well as a pigmentary condition. Useful background for explaining why heat, flushing and inflammation matter so much.
American Journal of Clinical Dermatology, 2024.
The most current American overview. Covers newer agents and the expert consensus on topical tranexamic acid.
Medscape, continuously updated.
Free, clinically detailed and heavily referenced. A practical starting point without journal access.
4.2 International consensus and reviews
Journal of the European Academy of Dermatology and Venereology, 2026.
The current international benchmark. Twenty-one statements reached high consensus. If you read one thing, this is it.
International Journal of Dermatology, 2025. Open access.
Practical and algorithmic. Contains the mMASI decision framework that underpins the escalation logic above.
Clinical, Cosmetic and Investigational Dermatology, 2023. Open access.
The pathophysiology paper. Explains why melasma is a dermal and vascular condition rather than a surface pigment deposit.
Handel AC, Miot LDB, Miot HA. Anais Brasileiros de Dermatologia, 2014. Open access.
The source of most of the Fitzpatrick prevalence data quoted above.
StatPearls, National Center for Biotechnology Information.
Free, comprehensive, continuously updated and written at clinical level.
Frontiers in Pharmacology, 2024. Open access.
Every topical, systemic and procedural option, with an honest account of where each falls short.
Open access literature review.
Everything on tranexamic acid in one place, covering oral, topical and intradermal routes and the safety profile.
Open access, 2023.
Balanced account of efficacy against side effects, and the international regulatory position including the EU cosmetic ban.
4.3 Patient-friendly resources
DermNet, New Zealand.
The best all-round resource on this list. The one to send a client home with.
British Association of Dermatologists, Patient Hub.
Written and readability-tested specifically for patients by a national dermatology body. Calm, non-commercial and authoritative.
British Association of Dermatologists, June 2024.
The printable version, for handing something physical to a client at the end of a consultation.
Cleveland Clinic.
Very accessible. Covers the hormonal triggers in plain language and lists the everyday aggravators.
Section Five
Important Notice and Terms of Use
This notice forms part of this material and applies to all of it. Please read it before using anything set out above.
1. This is educational material, not medical advice
This has been prepared for educational and informational purposes only. It is a summary of publicly available, peer-reviewed clinical literature and published international consensus guidance on the management of melasma. It does not constitute medical advice, diagnosis, or treatment, and it must not be relied upon as a substitute for consultation with a doctor, dermatologist, pharmacist, or other appropriately qualified and registered healthcare professional.
2. The author is not a medical practitioner
Valerie Osborne is an aesthetic practitioner, clinic owner and educator with more than twenty years of experience in the aesthetics industry. She is not a doctor, dermatologist, nurse, pharmacist or prescriber. She does not diagnose medical conditions and she is not qualified or authorised to prescribe, recommend or supply prescription medicines. Where prescription-only agents are described, they are described only to explain what the published clinical literature reports about them, so that non-prescribing practitioners understand the wider context in which they work and can recognise when to refer a client onward. Nothing here is a recommendation to use, obtain or supply any prescription medicine.
3. Prescription medicines and referral
A number of the agents discussed in Section Two are classified as prescription-only medicines in Ireland and in most other jurisdictions. They may lawfully be prescribed only by a registered prescriber, following an individual clinical assessment of the patient, and they carry contraindications and potential adverse effects that are not fully described here. They must never be obtained from unregulated sources, imported privately, or supplied by anyone not legally authorised to do so. If you or your client wish to explore these options, the correct and only route is a referral to a GP, dermatologist or other registered prescriber.
4. No practitioner or client relationship is created
Reading, downloading or applying this information does not create a professional, clinical or advisory relationship of any kind between the reader and Valerie Osborne or Elysium Skincare Clinic. No responsibility or liability is accepted for any action taken, or not taken, on the basis of the information contained here.
5. Practitioners remain responsible for their own practice
If you are a practitioner, you remain solely responsible for working within your own scope of practice, qualifications, training, insurance and the law of the country in which you practise. You are responsible for satisfying yourself as to the regulatory status of any product or device you use, for obtaining informed consent, and for carrying appropriate professional indemnity cover. Regulations governing cosmetic ingredients, medical devices and medicines differ between jurisdictions and change over time. Check the current position for your own country before acting.
6. Currency and accuracy
The clinical guidance summarised here reflects published literature and consensus statements available at the time of writing. Medicine changes. Guidance is superseded. Every effort has been made to represent the sources accurately, but no warranty is given as to completeness or continued accuracy, and readers are encouraged to consult the primary sources in Section Four directly.
7. No commercial endorsement
No brand, product, device or manufacturer is endorsed here, and no payment or commercial consideration has been received in connection with the preparation of this material. Ingredients and agents are referred to generically.
8. Seek medical attention where appropriate
If you have a skin concern, particularly a pigmented area that is changing, asymmetric, bleeding, painful or growing, seek assessment from a doctor without delay. Not all facial pigmentation is melasma, and some conditions that resemble it require urgent medical attention.